Trump’s new Executive Order on robotics is the first true catalyst this sector has had in years. Regulation usually slows innovation, but this time Washington accidentally poured gasoline on an industry that has been quietly building the next industrial supercycle.

Most people will sprint to Twitter and fire off hot takes. CNBC will mispronounce half these tickers. And the majority will chase whatever pops first.

But robotics is not one category — it’s an ecosystem. Hardware, software, automation, medical robotics, defense robotics, logistics robotics… each with its own leaders, laggards, and hidden gems.

Here’s the cleanest breakdown of the space:

Now let’s get into what actually matters — the names that stood out on my first pass, based on a blend of fundamentals, technicals, and my personal portfolio framework.

These aren’t consensus picks. These are the types of early mispricings I’ve built Alpha Before It Prints on.

Everything below reflects my own portfolio lens, not financial advice.
Ratings: Buy / Small Buy / Small Spec Buy / Watch

Rating: Buy

PATH crushed earnings today — clean beat across the board, margin expansion, top-line strength, and guidance that puts them back in the driver’s seat of enterprise automation.

PATH isn’t a follower in this trend — it is the automation trend.
And with the chart turning a major corner, this is a legit Buy for me.

Rating: Buy

Tesla’s auto numbers look rough right now — no sugarcoating it.
Margins have compressed, ASPs slid, profits per vehicle dropped, and inventory days are climbing. The charts lay it all out clearly:

This is exactly why everyone on FinTwit is bearish.

But here’s where they’re missing the plot:

Tesla’s stock is no longer priced on today’s auto business — it’s priced on the optionality of autonomy, robotics, and their AGI-driven future.

Let’s walk through the real data that matters:

Energy is becoming Tesla’s AWS — the reliable, scaling, high-margin business that Wall Street still values like a side hustle.

Despite the softness in auto, Tesla’s total revenue still grinds higher, and OpEx remains relatively flat.

The chart says it plain:

Revenue up.
OpEx flatish.

That’s the recipe for future margin expansion once the cycle turns.

This is why TSLA remains a Buy for me.

• Full Self-Driving (FSD)
If FSD solves even 80% of real-world driving, the financial model changes from selling cars to selling software + licensing an autonomy stack.

• Robo-taxi network
This is the holy grail — a global ride-hailing platform that operates with near-zero labor cost.
Uber with 100% margin on the driver side.

• Optimus
Tesla’s humanoid robot is the biggest underpriced asset in the entire robotics sector:

If Optimus hits commercial viability, Tesla becomes the first trillion-dollar robotics company.

• Real-world AI
No one else on the planet has billions of real-world miles to train an AI system capable of autonomy + robotics. That is Tesla’s true monopoly.

You’re not buying auto margins.
You’re buying the world’s largest real-world AI training engine.

Cash rising.
Debt shrinking.
Negative quarters don’t kill Tesla — they give them a reset while competitors bleed out.

TSLA is in a long basing structure — the kind of multi-month reset that historically precedes massive multi-year runs when the narrative flips.

Catalyst for that narrative flip?

Anything autonomy.
Anything robotaxi.
Anything Optimus.

Auto numbers suck.
Energy is quietly ramping.
Margins are cyclical.
But autonomy + robotics is forever.

TSLA is a Buy because it’s not a car company anymore — it’s the most advanced real-world robotics platform in the world, and the world still hasn’t priced that in.

Rating: Watch

Great higher-low setup. Clean pivot to define risk.
But I want confirmation before allocating capital here.

Rating: Small Buy

Microcap + high risk + early bottoming behavior.
Forward estimates look bullish.

This is a “toe-in-the-water” position — a small buy, not a full swing.

Rating: Buy

One of the cleanest bottoming structures in med-robotics. Accumulation showing up. But the real story is that PRCT is moving toward cash-flow positive operations.

Once a small-cap robotics company can fund its own growth:

This is a textbook early-cycle Buy for me. Chart looks to have found a bottom.

Rating: Buy

This is the name everyone calls “fully valued”…
until they actually read the numbers.

Here’s what’s happening under the hood:

• 23% revenue growth + massive EPS double beat
ISRG posted $2.40 EPS vs $1.99 expected, with 23% revenue growth — a $100M beat.
This is not how $200B med-tech companies usually behave.
This is acceleration.

• 19% procedure growth is the key
Procedures drive recurring revenue, operating leverage, and future upgrades.
ISRG crushed expectations here too.

• dV5 rollout is becoming an upgrade super-cycle
427 systems installed in Q3, with projected 17–17.5% growth ahead.

• Operating income up 30%
Free cash flow per share is now $6.36.
Substantial leverage emerging.

• EPS runway toward $10+
If they execute even moderately, ISRG can push toward double-digit EPS.

Technical setup:
A golden cross is imminent.
RSI made new highs.
Stock is consolidating just under heavy resistance at $600 — classic pre-breakout behavior.

Analysts can call it a Hold.
I call it a Buy.

This is how multi-year compounders set up before the next leg.

Rating: Buy (Small — startup stage)

SERV is still essentially a startup, which means the only way to approach it is with disciplined, small sizing — but the setup continues to be one of the better asymmetric plays in early-stage robotics.

Pushing straight into a major supply zone. This level has rejected price multiple times, so a short-term pullback or consolidation here wouldn’t surprise me. That’s normal behavior when you hit real overhead supply for the first time.

But the structure underneath it is what matters:

SERV has a proper multi-month bottom, reclaimed trend, and is now knocking on the first door that needs to break before a bigger move can happen.

Forward estimates look strong for a company this early in its lifecycle.
If they execute, the rerating won’t be subtle.

• Buy shares for the long term — treat it as an early, high-upside robotics bet if the business proves itself.
• Calls sized small — sized for 0, so a total loss doesn’t matter, but the upside is meaningful if SERV delivers. - March 20, 2026 $15

This matches the reality: SERV is early. High potential, high volatility.
You use shares to participate in the long-term story — and small, defined-risk calls to amplify the upside without letting the downside hurt you.

Short-term consolidation is likely, but the structural setup hasn’t changed.
SERV remains a small, high-upside long-term buy, with the options sized small enough that a complete 0 is acceptable.

Rating: Watch

Bottoming structure looks almost ready.
Estimates improving.
But I want another signal before stepping in.

Rating: Watch

Strong defense-robotics name with a chart that wants higher — but needs confirmation.

Rating: Buy

Bottoming process looks real.
Fundamentals strong.
If robotics becomes a national priority, KTOS will catch a bid quickly.

Rating: Watch

Large-cap defense robotics exposure.
Chart looks constructive.
But not actionable yet.

Rating: Buy

One of the most bullish charts in the entire sector.

Fundamentals could be stronger, but price action is undeniable — and price always leads.

Rating: Small Spec Buy (startup stage)

RR has one of the cleanest microcap robotics charts you’ll find — clear accumulation, tight ranges, and a textbook base.

But again:
RR is still basically a startup.

That means:

My approach:
March 20, 2026 $5 calls — defined risk, unlimited upside. Same sizing as SERV.

Everyone will chase the obvious robotics names.
But the real money is always made before the narrative forms — in the companies that look “too early” until suddenly they aren’t.

This Executive Order didn’t create the robotics supercycle.
It just exposed how badly the market has been mispricing it.

This is the moment where early conviction pays.

— Connor
Alpha Before It Prints

🔗 Connect with me:
✖️ Twitter | 💼 LinkedIn | 🚀 Subscribe

© 2025 Alpha Before It Prints
Unsubscribe